179 related articles for article (PubMed ID: 36151566)
21. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
Wang T; Subramanian C; Blagg BSJ; Cohen MS
Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
[TBL] [Abstract][Full Text] [Related]
22. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
23. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
25. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
[TBL] [Abstract][Full Text] [Related]
26. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.
Hadjadj D; Kim SJ; Denecker T; Ben Driss L; Cadoret JC; Maric C; Baldacci G; Fauchereau F
Aging (Albany NY); 2017 Dec; 9(12):2695-2716. PubMed ID: 29283884
[TBL] [Abstract][Full Text] [Related]
27. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.
Nilubol N; Boufraqech M; Zhang L; Gaskins K; Shen M; Zhang YQ; Gara SK; Austin CP; Kebebew E
Oncotarget; 2018 Aug; 9(68):33030-33042. PubMed ID: 30250647
[TBL] [Abstract][Full Text] [Related]
28. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
[TBL] [Abstract][Full Text] [Related]
29. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
30. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
[TBL] [Abstract][Full Text] [Related]
31. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
32. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
33. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
34. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells.
Maria AG; Silva Borges K; Lira RCP; Hassib Thomé C; Berthon A; Drougat L; Kiseljak-Vassiliades K; Wierman ME; Faucz FR; Faça VM; Tone LG; Stratakis CA
Mol Cell Endocrinol; 2021 May; 528():111243. PubMed ID: 33716050
[TBL] [Abstract][Full Text] [Related]
36. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
37. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
38. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
40. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
Ikeda Y; Sato S; Yabuno A; Shintani D; Ogasawara A; Miwa M; Zewde M; Miyamoto T; Fujiwara K; Nakamura Y; Hasegawa K
J Gynecol Oncol; 2020 Nov; 31(6):e93. PubMed ID: 33078598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]